VIATRIS INC. Estimated Litigation Liability, Current
VIATRIS INC. (VTRS) had Estimated Litigation Liability, Current of $303.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LitigationReserveCurrent · last filed 2026-08-06
- 2026-06-30: Estimated Litigation Liability, Current $303.00M.
- 2026-03-31: Estimated Litigation Liability, Current $293.70M.
- 2025-12-31: Estimated Litigation Liability, Current $326.30M.
- 2025-09-30: Estimated Litigation Liability, Current $556.30M.
| Period end | Estimated Litigation Liability, Current |
|---|---|
| 2026-06-30 | $303.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $293.70M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $326.30M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $556.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $540.80M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $525.60M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $472.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $446.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $453.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $321.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $244.00M 10-K · filed 2025-02-27 |
| 2023-09-30 | $205.50M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $252.10M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $288.80M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $297.20M 10-K · filed 2024-02-28 |
| 2022-09-30 | $397.40M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $676.30M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $694.90M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $715.60M 10-K · filed 2023-02-27 |
| 2021-09-30 | $474.90M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $487.70M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $481.90M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $362.90M 10-K · filed 2022-02-28 |
| 2019-12-31 | $138.20M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |